Texas Med Spa Regulatory Changes 2026: TMB Rule 169.28, HB 3749 (Jenifer's Law) & FDA Enforcement

The Texas regulatory environment for med spas has moved more in the last 18 months than in the prior decade. The Texas Medical Board's comprehensive January 2025 rule package, the legislative session's HB 3749, and the FDA's April 2026 warning letter to a Texas operator together represent three independent enforcement vectors landing on the same operator profile at the same time. Operators who navigated the pre-2025 environment by assuming "the rules will catch up later" are now operating in a state where the rules have, in fact, caught up.

This guide covers the three changes that matter, what they actually require, the bills that did not pass (which operators also need to understand), and the concrete steps every Texas med spa should take before the next TMB inspection, DSHS visit, or FDA letter.

The Three 2025–2026 Changes Every Texas Med Spa Must Understand

Like California and New York, Texas's recent changes come from different sources — the Texas Medical Board, the Texas Legislature, and the FDA. Each one independently affects most Texas med spa operations. Together they signal a structurally tighter environment.

TMB Rule 169.28 and Related Rule Changes (January 9, 2025)

The most consequential change. The Texas Medical Board adopted comprehensive rule revisions taking effect January 9, 2025, that explicitly recognize non-surgical medical cosmetic procedures as the practice of medicine, require all delegation to be documented in writing, and impose physician posting and staff identification requirements at every Texas med spa. The rule reforms close longstanding ambiguity about what qualifies as the practice of medicine in Texas aesthetic settings — and impose visible compliance requirements that an inspector can verify in 60 seconds of walking through a facility. The TMB's official rule changes page is the primary source.

HB 3749 — Jenifer's Law (Signed June 20, 2025; Effective September 1, 2025)

Signed by Governor Abbott in June 2025 and effective September 1, HB 3749 — Jenifer's Law — was originally drafted to cover cosmetic medical treatments and medical spas broadly, but the enacted version was scoped down to focus exclusively on elective IV therapy. The law requires that IV treatments at IV therapy centers be administered by an RN or above. The Holland & Knight summary of the signing and the Dykema implementation analysis both detail how the law applies to operators with IV therapy service lines.

The FDA Warning Letter to Pure Indulgence Aesthetics (April 1, 2026)

On April 1, 2026, the FDA issued a warning letter to Pure Indulgence Aesthetics in Southlake, Texas following a multi-day inspection conducted in December 2025. The inspection focused on the practice's handling of botulinum neurotoxin type A products (Botox), regulated as prescription drugs under federal law. The American Med Spa Association coverage of the warning letter walks through the underlying violations. Federal enforcement actions against individual aesthetic practices were rare a decade ago; the Pure Indulgence letter signals that they are no longer rare.

TMB Rule 169.28: Cosmetic Procedures Explicitly Recognized as Practice of Medicine

Before January 9, 2025, Texas med spa operators could (and often did) operate in regulatory gray areas around what counted as "the practice of medicine" versus "a cosmetic service." Many practices structured their delegation, supervision, and ownership arrangements around the ambiguity. The TMB rule changes eliminated the gray area.

The Practice-of-Medicine Recognition

The TMB rules now explicitly state that non-surgical medical cosmetic procedures — including neuromodulator injections, dermal fillers, laser treatments, medical microneedling, RF energy devices, and similar treatments — are the practice of medicine in Texas. The consequences cascade:

• Only physicians (MDs, DOs) and properly delegated mid-level providers (APRNs, PAs) operating under written delegation can perform these procedures
• The entity owning and operating the practice must be a physician-owned professional entity under the Texas Corporate Practice of Medicine doctrine
• The supervising physician bears the same legal responsibility for outcomes that any physician bears for medicine practiced under their supervision
• TMB has jurisdiction over the practice in the same way it has jurisdiction over any other medical practice in Texas

For operators who had been running a med spa with informal ownership structures, casual delegation, or non-physician supervision, the rule changes converted longstanding operational habits into immediate compliance violations. The remediation path is straightforward but not optional: physician ownership, written delegation, and clear supervision documentation. For deeper Texas medical director context, see our Texas med spa medical director requirements guide.

What Counts as "Cosmetic Medical Practice"

The TMB's interpretation captures most of the modern med spa service menu:

• Neuromodulator injections — Botox, Dysport, Xeomin, Daxxify
• Dermal fillers — hyaluronic acid fillers, biostimulators like Sculptra and Radiesse
• Laser treatments — laser skin resurfacing, vascular lasers, pigmented lesion lasers, laser hair removal (specific delegation rules apply)
• RF microneedling and medical microneedling — including PRP-combined microneedling
• Chemical peels at medical depths — TCA peels, deeper Jessner peels
• Body contouring devices — energy-based modalities classified as medical
• Prescription weight-loss medications — GLP-1 receptor agonists including semaglutide and tirzepatide (see our TX GLP-1 compliance guide)
• Hormone replacement therapy — TRT, HRT, BHRT including pellet insertion (see our Texas hormone therapy compliance guide)
• IV therapy — covered both by the TMB rule and HB 3749's specific RN-or-above administration requirement

The New Written-Delegation Requirement: Standing Orders, Protocols, and PAAs

The second pillar of the 2025 TMB rules is the documentation requirement for delegation. Every delegated act must now be authorized through a specific written instrument. Informal delegation, verbal authorization, and "we have a standing arrangement" are no longer recognized.

The Four Recognized Delegation Instruments

Under the updated rules, delegation must occur through one of four written instruments:

1. Standing Delegation Orders — written instructions from a physician to specifically named delegates (RN, MA, or other qualified staff) authorizing them to perform specific acts under defined conditions on patients who meet specified criteria
2. Standing Medical Orders — written protocols issued to an entire class of delegates (e.g., "any RN at this facility") authorizing a specific procedure or set of procedures on patients meeting defined criteria
3. Protocols — clinical treatment protocols approved by the supervising physician that govern specific service lines (Botox protocol, filler protocol, IV therapy protocol, GLP-1 prescribing protocol)
4. Prescriptive Authority Agreements (PAAs) — required for APRNs and PAs prescribing medications under physician delegation. PAAs must define the scope of delegated prescribing authority, the categories of medications covered, controlled substance restrictions, and the oversight model

Verbal or informal delegation is no longer recognized. A physician who authorized an RN to do Botox injections "back when I signed on as medical director" but never put it in writing is not a compliant delegation — it is no delegation at all, and the RN performing those injections is exposed to nursing board action and the physician is exposed to TMB discipline.

What the Written Documentation Must Include

For each delegated act, the documentation must specify:

• The act being delegated (specific procedure, specific drug, specific scope)
• Who may perform it (named individual or class of delegates)
• Under what conditions (patient eligibility, pre-treatment requirements, contraindication screening)
• What supervision is required (physician availability, chart review, escalation criteria)
• The duration of the delegation (typically up to one year before renewal)
• The signature and date of the delegating physician

For more on Texas-specific delegation for injectables, see our Texas Botox delegation rules guide.

The New Transparency Rules: Physician Posting and Staff ID Requirements

The third pillar of the 2025 TMB rule changes is the visibility requirement. The board added concrete, inspectable, walking-through-the-door rules that change what every Texas med spa looks like on the inside.

The Physician Posting Requirement

Every facility performing delegated medical acts must post the following information in all public areas and treatment rooms:

• The delegating physician's name — full legal name as on the TMB license
• The physician's TMB license number — the public-facing license number, not a personal identifier
• A notice of how to file a complaint with the Texas Medical Board — including the TMB complaint phone number and website

"All public areas and treatment rooms" is interpreted broadly. The lobby, the consultation room, every treatment room, and any other space patients access during a visit all need the posting. A single sign at the front desk is not sufficient. The posting must be in a location reasonably visible to patients in each space.

The Staff Identification Requirement

Every staff member performing a delegated medical act must wear identification showing:

• Their name
• Their credentials — specifically the license type that authorizes the act they are performing (e.g., "Jane Smith, RN" not just "Jane")

The point of the ID requirement is that patients can verify the credentials of the person treating them. An esthetician who is performing a delegated act under physician supervision must wear ID showing they are an esthetician — not a generic name tag. The TMB explicitly rejected proposals to allow generic role-based titles.

Why These Rules Have Outsized Impact

The posting and ID rules are the easiest compliance items to verify and the easiest to violate accidentally. A TMB inspector or DSHS investigator walking through a facility can document violations in the first 60 seconds — before any chart is opened, before any patient is interviewed, before any drug storage is examined. Combined with the practice-of-medicine recognition and the written delegation requirement, the posting and ID rules give inspectors a fast initial assessment of whether the facility is operating within current TMB expectations.

For an existing Texas med spa, the operational implication is concrete: physical signage in every patient-facing room, staff name badges with credentials, and a documented internal audit confirming compliance. The cost of compliance is trivial; the cost of being cited on the first walkthrough is substantial.

HB 3749 (Jenifer's Law): What It Actually Covers (and What Got Cut)

HB 3749 is the bill most often miscommunicated in Texas med spa industry discussions. The version that became law is significantly narrower than the version originally introduced — and operators need to understand the distinction.

What the Enacted Law Actually Requires

The version Governor Abbott signed on June 20, 2025 and that took effect September 1, 2025 covers elective IV therapy only. The original bill text included broader references to "cosmetic medical treatments" and "medical spas" — both of which were removed during the legislative process. The enacted law:

• Applies specifically to IV therapy centers — facilities whose primary or substantial service is the administration of IV vitamin, hydration, NAD+, or similar infusions
• Requires that the actual IV treatment be administered by an RN or above (LVN, medical assistant, esthetician, or unlicensed staff cannot administer)
• Does not impose facility licensing or new ownership requirements beyond existing TMB and TBN rules
• Does not impose new requirements on med spas that do not offer IV therapy

What Got Cut from the Bill

The original bill would have applied to a much broader category of "cosmetic medical treatments" performed at med spas. Industry advocacy successfully narrowed the scope during the legislative process. Operators reading older summaries of the bill should not assume the broader scope applies — the enacted text controls, and it is limited to IV therapy.

Operational Implications for IV Therapy Operators

If your Texas med spa offers IV therapy, the practical compliance steps are:

1. Confirm that every IV treatment administration is performed by an RN or higher-credentialed provider (NP, PA, MD)
2. Update intake and treatment workflow documentation to reflect the RN-or-above requirement
3. Audit staff schedules to ensure RN coverage during all hours IV services are offered
4. Update job descriptions and hiring requirements for any roles that previously included IV administration as a duty
5. Confirm RN delegation documentation (standing orders or protocols) for the specific IV preparations administered

What "Or Above" Means

HB 3749 specifies "RN or above," which in Texas means: Registered Nurse (RN), Advanced Practice Registered Nurse (APRN — includes Nurse Practitioners), Physician Assistant (PA), Physician (MD or DO). Licensed Vocational Nurses (LVNs), medical assistants, certified nursing assistants, and unlicensed staff cannot administer IV treatments under the new law, regardless of supervision or training.

The Bills That Didn't Pass: SB 378 Veto and HB 3889/3890 — And Why It Matters

Informed Texas med spa operators need to understand not just what passed but what didn't. Two parallel legislative tracks in the 2025 session aimed to expand delegation flexibility for non-physician providers — and both failed to become law.

SB 378 — Vetoed by Governor Abbott (June 2, 2025)

SB 378 would have modified physician delegation authority under Texas Occupations Code Chapter 157. The bill passed both chambers but was vetoed by Governor Abbott on June 2, 2025. The veto preserved the existing Chapter 157 delegation framework — meaning the rules in place before SB 378 was introduced remain the operative rules today.

Operators who saw industry discussion of SB 378's potential impact during the legislative process should note: that impact never materialized. Any planning that assumed SB 378 would pass needs to be reset to the pre-2025 (and now TMB-tightened) baseline.

HB 3889 and HB 3890 — Died in Committee

HB 3889 and HB 3890 were companion bills aimed at adjusting various aspects of Texas health professions law. Both bills failed to receive a public hearing from the Public Health Committee before the May 15, 2025 deadline for second reading in the House. Without hearings, the bills did not advance and effectively died in committee.

The Practical Implication of Three Failed Bills

The 2025 Texas legislative session was unusual: significant industry-backed legislation aimed at clarifying or expanding delegation either passed in a narrowed form (HB 3749), was vetoed (SB 378), or died in committee (HB 3889/3890). The TMB's January 2025 rule changes — which the Board can make administratively without legislative action — proceeded independently and now define the operating environment more than any of the failed bills would have.

Operators tracking the political landscape should expect renewed legislative efforts in the 2027 session (Texas's legislature meets biennially in odd years). Operational planning should not, however, depend on legislative changes that have not yet been signed into law.

The Pure Indulgence FDA Warning Letter: Federal Enforcement on TX Soil

The April 1, 2026 FDA warning letter to Pure Indulgence Aesthetics in Southlake, Texas is the first widely publicized federal enforcement action against a Texas med spa specifically for drug-handling violations. It signals a new tier of regulatory exposure for operators who previously assumed FDA oversight was concerned only with manufacturers, distributors, and compounding pharmacies.

The Inspection Background

The FDA conducted a multi-day on-site inspection of Pure Indulgence Aesthetics in December 2025. The inspection focused specifically on the practice's handling of botulinum neurotoxin type A products — Botox and similar neuromodulators, which are regulated as prescription drugs under federal law. The April 1, 2026 warning letter documented the findings and gave the practice a window to respond before further FDA action.

What the FDA Cited

The warning letter detailed violations including issues around prescription drug handling, recordkeeping, and storage. The specific findings reflect what FDA inspectors look for during an aesthetic practice inspection:

• Sourcing and chain of custody — whether prescription drug products were obtained through manufacturer-authorized distributors with documented invoicing and lot tracking
• Storage conditions — temperature monitoring, refrigeration logs, and physical security of prescription drug stock
• Recordkeeping — patient-specific records of which product (by lot number) was administered to which patient on which date
• Prescription documentation — written orders or prescriptions backing each administered product
• Disposal procedures — handling of expired product and proper disposal documentation

Why This Matters Beyond Pure Indulgence

The warning letter is significant for three reasons. First, it confirms that FDA inspectors are now conducting multi-day on-site inspections of individual med spa operators — historically rare. Second, the inspection criteria the FDA applies are essentially the same criteria a pharmaceutical distributor would face — meaning med spas need to operate to pharmaceutical-grade product-handling standards. Third, federal enforcement layers on top of state TMB and DSHS enforcement, creating overlapping regulatory exposure that operators cannot address by satisfying state rules alone.

For advertising-side FDA exposure, see our Texas med spa FDA & FTC advertising compliance guide. The product-handling side covered here is a separate but parallel regulatory dimension.

APRN and PA Delegation in Texas: PAAs and What They Must Cover in 2026

Texas's restricted-practice framework for APRNs and PAs makes the Prescriptive Authority Agreement (PAA) the central compliance document for any med spa relying on mid-level providers — which most do.

The PAA Requirement

Under Texas law, an APRN or PA who prescribes medications must do so under a written Prescriptive Authority Agreement with a supervising or delegating physician. The PAA is not a generic delegation document; it must specifically address prescribing. Without a current PAA, an APRN or PA cannot legally prescribe even if they hold an individual DEA registration and even if they are otherwise within their scope of practice.

What a Compliant PAA Must Include

• Identification of the parties — full legal names, license numbers for both the physician and the APRN/PA, effective dates
• Scope of delegated prescribing — the specific medication categories the delegate is authorized to prescribe
• Controlled substance authorization — explicit authorization or exclusion for Schedule II, III, IV, and V controlled substances. Texas treats controlled substance delegation more strictly than non-controlled; Schedule II authority requires specific additional language
• Practice setting — the specific locations where the delegation applies
• Quality assurance plan — how the supervising physician will review the delegate's prescribing patterns; common practice is monthly chart review of at least 10% of the delegate's prescriptions
• Periodic review schedule — required review of the PAA itself at least annually with documented signature renewal
• Termination provisions — notice periods, immediate-termination conditions, and patient transition obligations

Schedule II Limits and Hormone Therapy

For Texas med spas offering controlled substance services — particularly testosterone replacement therapy and other hormone services — PAAs require explicit Schedule II–V authorization with specific drug category designation. Most general PAAs do not cover Schedule III controlled substances by default; the PAA must be specifically expanded. For the full Texas hormone therapy framework including DEA requirements layered on PAAs, see our Texas hormone therapy compliance guide.

Multi-Agency Enforcement: TMB, DSHS, FDA, DEA, BON

Texas med spa enforcement in 2026 involves five agencies that historically operated independently and increasingly share information.

Texas Medical Board (TMB)

The TMB is the primary state regulator for physicians and is the lead enforcer of the Rule 169.28 changes. TMB conducts inspections (often unannounced), investigates complaints, and pursues physician discipline for inadequate supervision, improper delegation, and unauthorized practice of medicine cases. TMB discipline ranges from reprimands and remedial education to license suspension and revocation.

Texas Board of Nursing (BON)

The Board of Nursing has jurisdiction over RNs, LVNs, and APRNs. When TMB inspections find scope-of-practice violations involving nurses, the matters are referred to the BON for nursing discipline. RNs working at non-compliant facilities can face BON action independently of any TMB action against the physician.

Texas Department of State Health Services (DSHS)

DSHS handles facility-level health and sanitation matters and regulates several specific service categories at med spas including tanning and permanent makeup. DSHS authority overlaps with TMB in some areas. For the broader DSHS inspection framework, see our Texas DSHS inspection and violations guide.

FDA

As Pure Indulgence demonstrates, the FDA is now conducting on-site med spa inspections focused on prescription drug handling. FDA enforcement runs federal — warning letters can escalate to formal enforcement actions, injunctions, and criminal referrals. FDA findings can also trigger parallel TMB, BON, and DEA actions.

DEA

The DEA has jurisdiction over any Texas med spa storing, dispensing, or administering controlled substances — Schedule III testosterone is the most common trigger. DEA registration is required for both the prescribing physician individually and the facility itself. DEA inspections can occur independently or as a result of FDA referrals.

Texas Attorney General

The AG handles unauthorized practice of medicine matters that rise to criminal violation, as well as broader consumer protection cases against operators with deceptive advertising or pattern-of-conduct violations. AG involvement is the highest-tier enforcement signal.

The Compliance Checklist for Texas Med Spas Before Any Inspection

Concrete items to verify, in priority order, before the next TMB visit, DSHS walkthrough, or FDA inspection.

Physician Posting and Staff ID

1. Confirm physician name, TMB license number, and TMB complaint notice are posted in every public area and treatment room
2. Confirm every clinical staff member has and wears an ID badge showing name and credentials
3. Document an internal audit confirming posting and ID compliance; date and sign by the medical director
4. Update postings and IDs whenever the medical director changes

Written Delegation Documentation

1. For every delegated act performed at the facility, confirm written delegation through standing orders, protocols, or PAAs
2. For APRNs and PAs, confirm current signed PAAs covering all prescribing activity, including controlled substance authorization where applicable
3. Confirm each delegation document is signed and dated by the supervising physician within the last 12 months
4. Maintain a single binder or digital folder organized by delegate, with delegation documents accessible immediately on inspector request

Ownership and CPOM Structure

1. Confirm the clinical entity is owned by a Texas-licensed physician or physician-owned professional entity
2. If operating through an MSO structure, confirm the MSO provides administrative services only and the physician-owned PC retains clinical authority
3. Review the Management Services Agreement against TMB CPOM expectations; rewrite any language that gives the MSO clinical decision-making authority

IV Therapy Compliance (If Applicable)

1. Confirm every IV treatment is administered by an RN or above per HB 3749
2. Update workflow, intake, and scheduling to enforce the RN-or-above requirement
3. Audit staff schedules for RN coverage during all IV service hours

Prescription Drug Handling (Botox and Other Injectables)

1. Confirm all injectable products are sourced through manufacturer-authorized distributors; maintain invoices and lot tracking records
2. Maintain temperature monitoring logs for refrigerated injectable products
3. Maintain patient-specific records of which product (by lot number) was administered to which patient on which date
4. Maintain written orders or prescriptions backing each administered product
5. Document expired product disposal procedures
6. Review the Pure Indulgence warning letter findings as a self-audit checklist

Controlled Substances (If Applicable)

1. Confirm DEA registration for both the prescribing physician and the facility location if Schedule III–V substances are stored on-site
2. Maintain biennial inventory records and dispensing logs per DEA requirements
3. Confirm PAAs covering APRN/PA controlled substance prescribing

Facility Sanitation and OSHA

1. Confirm OSHA Bloodborne Pathogen Standard compliance — sharps disposal, single-use item handling, surface disinfection
2. Document staff training on infection control and bloodborne pathogen safety
3. Maintain incident logs for any needle sticks or exposure events

Adjacent compliance is covered in our existing Texas posts; the items above add the specific 2025–2026 layer on top.

How Texas Compares to California and New York's 2026 Environments

Each of the big three med spa markets has moved in 2026, but the operative drivers differ.

vs California

California's 2026 changes are primarily legislative — SB 351 codifying CPOM against private equity, AB 1415 expanding OHCA pre-transaction notice, and the Medical Board's PSO enforcement shift. Our California 2026 regulatory changes guide walks through the full picture. CA emphasizes ownership structure and clinical authorization documentation; TX emphasizes board-level rule reforms and federal product-handling enforcement.

vs New York

New York's 2026 environment is dominated by a multi-agency enforcement task force that conducted 223 inspections and issued 87 citations in its first wave — covered in our New York 2026 regulatory changes guide. New York's changes are operational and enforcement-led rather than rule-driven; Texas's are rule-driven plus FDA federal enforcement. Both states are tightening; the mechanisms differ.

The Common Thread

The three biggest med spa markets in the country are all moving in the same direction in 2026: tighter delegation documentation, more aggressive enforcement, and overlapping multi-agency exposure. Operators running multi-state platforms should expect the patterns to spread — what happened first in CA, NY, and TX in 2026 will likely appear in other markets within 18–24 months. For state-by-state context, see our med spa regulations by state pillar.

Summary

1. Three changes have reshaped the Texas med spa regulatory environment in 2025–2026: TMB Rule 169.28 (effective Jan 9, 2025), HB 3749 / Jenifer's Law (effective Sept 1, 2025), and the FDA's April 1, 2026 warning letter to Pure Indulgence Aesthetics
2. TMB Rule 169.28 explicitly recognizes non-surgical cosmetic procedures as the practice of medicine and imposes written delegation, physician posting, and staff ID requirements
3. HB 3749 requires that IV therapy at IV therapy centers be administered by an RN or above; the law does not apply to med spas without IV service lines
4. The FDA warning letter signals that federal enforcement is now landing on individual TX med spa operators for prescription drug handling violations
5. SB 378 was vetoed by Governor Abbott in June 2025; HB 3889 and HB 3890 died in committee — operators should not plan around legislation that did not become law
6. APRN and PA prescribing in Texas requires a current Prescriptive Authority Agreement (PAA) with specific Schedule II–V authorization for controlled substance categories
7. Multi-agency exposure: TMB, BON, DSHS, FDA, DEA, and the Texas AG all have overlapping jurisdiction; an inspection by any one can trigger referrals to the others
8. Physician posting, staff ID, written delegation, and product-handling documentation are the highest-leverage compliance items to address before the next inspection

Disclaimer: This article is for educational purposes only and does not constitute legal advice. Texas's regulatory environment involves overlapping state and federal authorities and active enforcement. Consult a Texas healthcare attorney for advice specific to your practice structure, location, and procedure mix.